Tigatuzumab
Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5) . Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer[1].
Product Specifications
CAS Number
918127-53-4
Product Name Alternative
CS-1008; Anti-Human TRAIL-R2 Recombinant Antibody
UNSPSC
12352203
Target
Apoptosis
Type
Inhibitory Antibodies
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tigatuzumab.html
Purity
99.90
Solubility
10 mM in DMSO
Smiles
[Tigatuzumab]
Molecular Weight
(144.64 kDa)
References & Citations
[1]Yamamoto J, et al. Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model. Cancer Lett. 2020 Nov 1;492:174-184.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
